BCRX vs MAZE: stock comparison and AI forecast
Biocryst Pharmaceuticals Inc (BCRX) and Maze Therapeutics, Inc. (MAZE) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
BCRX Biocryst Pharmaceuticals Inc
- Price
- $7.63 -14.3% · 6M
- Market Cap
- $1.95B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
MAZE Maze Therapeutics, Inc.
- Price
- $33.38 +26.1% · 6M
- Market Cap
- $1.81B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- BCRX and MAZE have similar market capitalizations ($1.95B and $1.81B).
- Over the last six months MAZE returned +26.1% and BCRX -14.3%.
- BCRX turns -37.4% of its revenue into net income, against -334.0% for MAZE.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | BCRX | MAZE |
|---|---|---|
| Market Cap | $1.95B | $1.81B |
| P/B Ratio | – | 3.99x |
| EPS | $-1.30 | $-1.89 |
| Book Value/Share | – | $8.16 |
| Revenue/Share | $3.76 | – |
| FCF/Share | $1.43 | $-1.92 |
Profitability & Margins
| Metric | BCRX | MAZE |
|---|---|---|
| ROE | – | -29.5% |
| ROA | -60.8% | -25.1% |
| ROIC | -73.2% | -28.6% |
| Gross Margin | 97.9% | – |
| Operating Margin | -30.1% | -364.0% |
| Net Margin | -37.4% | -334.0% |
| EBT Margin | -36.9% | -281.7% |
| Tax Rate | -1.4% | – |
Financial Health
| Metric | BCRX | MAZE |
|---|---|---|
| Current Ratio | 2.71x | 18.31x |
| Quick Ratio | 2.64x | – |
| D/E Ratio | – | 0.17x |
| Financial Leverage | – | 1.17x |
| Interest Coverage | 6.3x | – |
| Working Capital | $335M | $397M |
Cash Flow
| Metric | BCRX | MAZE |
|---|---|---|
| Operating Cash Flow | $367M | -$107M |
| Free Cash Flow | $366M | -$107M |
| Capital Spending | -$2M | -$300K |
| OCF Growth YoY | 632.1% | – |
| FCF Growth YoY | 658.3% | – |
| FCF/Sales | 38.0% | – |
| CapEx/Sales | 0.2% | – |
Operational Efficiency
| Metric | BCRX | MAZE |
|---|---|---|
| Asset Turnover | 1.63x | – |
| Receivables Turnover | 7.9x | – |
| Inventory Turnover | 1.5x | – |
| Fixed Assets Turnover | 578.5x | – |
| Days Sales Outstanding | 46 days | – |
| Days Inventory | 247 days | – |
| Payables Period | 262 days | – |
| Cash Conversion Cycle | 31 days | – |
Income Statement
| Metric | BCRX | MAZE |
|---|---|---|
| Total Revenue | $962M | – |
| Operating Income | -$289M | -$146M |
| Net Income | -$360M | -$134M |
| R&D Expense | $211M | $122M |
| SG&A Expense | $321M | – |
| Cost of Goods Sold | $20M | – |
Dividend & Shareholder Information
| Metric | BCRX | MAZE |
|---|---|---|
| Shares Outstanding | 256M | 56M |
BCRX vs MAZE: stock comparison and AI forecast
Which is bigger, BCRX or MAZE?
BCRX and MAZE have similar market capitalizations ($1.95B and $1.81B).
Which stock performed better over the last six months, BCRX or MAZE?
Over the last six months MAZE returned +26.1% and BCRX -14.3%.
Which one does Intratio's AI model rank higher, BCRX or MAZE?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.